Tennessee Clinical Trials Report — June 2026

For Tennesseans considering participation in clinical research, June 2026 presents both urgent opportunities and exciting new avenues. A total of 102 clinical trials across the state are scheduled to conclude within the next 90 days, meaning the window for enrollment is rapidly closing. Among these are 13 studies actively seeking healthy volunteers, offering a chance to contribute to medical advancements without a specific health condition.

Patients with certain health conditions should also review trials nearing their end. Studies focusing on various cancers and cardiovascular issues are prominent among those with limited time remaining for new participants. Conditions with trials closing soon include:

• Breast cancer (4 trials)
• Prostate cancer (3 trials)
• Cardiovascular diseases (3 trials)
• Leukemia, myeloid, acute (2 trials)
• Gestational diabetes mellitus in pregnancy (2 trials)
• Leukemia, myeloid (2 trials)
• Colorectal cancer (2 trials)
• Autonomic failure (2 trials)
• Cancer (2 trials)
• Advanced malignant neoplasm (2 trials)

New Horizons in Tennessee Research

This month, Tennessee welcomes 37 new clinical trials, matching the number of new studies that opened in May 2026. These new initiatives include several significant Phase 3 drug and vaccine trials from major pharmaceutical companies, offering participants access to innovative treatments for widespread health challenges and crucial preventive measures.

• AstraZeneca is sponsoring NCT07667803, a Phase 3 "Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM." This substantial global study aims to enroll 4,500 participants, evaluating a new treatment for weight management.
• Another major Phase 3 trial, NCT07654361, is "Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)," sponsored by Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics. This global study seeks 3,600 participants to assess the long-term efficacy and safety of aleniglipron.
• Pfizer is leading two important Phase 3 vaccine trials. NCT07629440, "A Study to Learn About How a New Pneumococcal Vaccine Works in Infants," aims for 3,230 participants to evaluate the safety and immune response of a new vaccine against pneumonia, meningitis, and otitis media in infants. Additionally, NCT07660198, "Study to Learn About Safety, Tolerability, and Immune Response of a Catch-up Pneumococcal Vaccine in Children and Adolescents," will enroll 1,200 participants to assess a new pneumococcal vaccine in older children.
• For those with type 2 diabetes, AstraZeneca is also sponsoring NCT07662109, a Phase 3 study investigating "The Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus." This trial plans for 2,000 participants.
• Individuals experiencing migraines may be interested in NCT07645924, "A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine," a Phase 3 trial sponsored by Kallyope Inc., targeting 1,800 participants.
• An important observational study, NCT07625579, "Collaboration for Down Syndrome Progress (CDP)," sponsored by RTI International, is seeking 1,400 participants of all ages to better understand the health, development, and everyday experiences of people with Down syndrome over time.
• For bladder cancer detection, Convergent Genomics, Inc. is sponsoring NCT07673016, "Specimen Collection for Validation of UroAmp: A Next Generation Sequencing Platform for Detection and Surveillance of Bladder Cancer," which aims to collect biospecimens from 2,500 participants.

Opportunities for Healthy Volunteers

For individuals without a specific medical condition, there are valuable opportunities to contribute to medical science. Of the 37 new trials launched this month, 6 are actively seeking healthy volunteers. Statewide, a total of 135 clinical trials are currently recruiting healthy participants, providing numerous avenues for those interested in supporting medical research and advancing health knowledge.

Geographic Spread of Research Across Tennessee

Tennessee's clinical research landscape remains dynamic, with 1,934 clinical trials currently recruiting across 54 cities and 1,051 research sites statewide. This month, new research initiatives are concentrated in several key metropolitan areas, ensuring accessibility for many residents:

• Nashville (17 new trials)
• Memphis (10 new trials, including one listed as "Mephis")
• Knoxville (6 new trials)
• Tullahoma (2 new trials)
• Chattanooga (2 new trials)
• Kingsport (2 new trials)

Smaller communities also saw new trial openings, including Martin, Franklin, and Elizabethton, demonstrating a continued effort to broaden the reach of clinical research beyond the major cities.

Diverse Conditions and Participant Demographics

The 37 new trials opening this month in Tennessee cover a diverse range of health conditions, with a strong focus on metabolic health, infectious disease prevention, and rare genetic disorders. The most common conditions addressed by these new studies include:

• Obesity, overweight, and chronic weight management (7 trials)
• Type 2 diabetes mellitus (5 trials)
• Pneumococcal disease (2 trials)
• Duchenne muscular dystrophy (DMD) (2 trials)

In terms of intervention types, drug trials lead the way, accounting for 23 of the new studies. Other types of research include biological treatments, procedures, behavioral interventions, and device studies. Clinical trials in Tennessee are designed to be inclusive, with a broad range of eligibility criteria. Of the new trials, 6 include children as participants, and 32 include older adults, ensuring that research benefits diverse age groups. One new trial is female-only, and another is male-only, indicating specific research needs.

Leading the Way: Key Sponsors in Tennessee

Both academic institutions and industry sponsors are driving significant research efforts in Tennessee. Industry sponsors are leading the charge with 23 new trials this month, including major pharmaceutical companies such as AstraZeneca (5 trials), Pfizer (2 trials), Novo Nordisk A/S (2 trials), Gasherbrum Bio, Inc. (2 trials), and Kallyope Inc. (2 trials). Academic institutions also play a vital role, with Vanderbilt University Medical Center sponsoring 4 new trials and St. Jude Children's Research Hospital sponsoring 3 new trials, highlighting their commitment to advancing medical knowledge and patient care.

As we navigate through June, the focus remains on encouraging participation in these vital clinical trials, from those nearing completion to the exciting new studies offering innovative approaches to health challenges across Tennessee.